Cabergoline versus calcium infusion in the prevention of ova
The effectiveness of cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in IVF patients at high risk for OHSS is confirmed by overwhelming scientific evidence. The study finds that calcium infusion and cabergoline have comparable effectiveness in the prevention of OHSS.

The aim of this study was to compare the efficacy of calcium infusion versus cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in IVF patients at high risk for OHSS.

170 patients who were stimulated using the long luteal GnRH agonist protocol and at high risk for developing OHSS were randomized in a 1:1 ratio to cabergoline group and calcium gluconate group. In the cabergoline group, 0.5?mg of cabergoline was administered once daily p.o. for eight days starting on the day of HCG administration. In the calcium gluconate group, intravenous calcium gluconate was administered daily for four days starting on the day of ovum pickup.

- Six patients in the cabergoline group and eight patients in the calcium gluconate group developed moderate OHSS. One patient in each group developed severe OHSS.

- The incidence of moderate/severe OHSS was comparable between both groups.

- The implantation, clinical, and ongoing pregnancy rates were similar in the two groups.

In conclusion, calcium infusion and cabergoline have comparable effectiveness in the prevention of OHSS. Both drugs are well tolerated, cheap, and have no adverse effects on the reproductive outcomes of the IVF cycle.

Journal of Obstetrics and Gynaecology
Source: https://doi.org/10.1080/01443615.2020.1870944
Like
Comment
Share